Table 2. Association of cirDNA with age.
| Authors (year) | Subject | Age analysed | Conclusion to age effect on cirDNA amount |
|---|---|---|---|
| Sozzi et al., 2001 | Control (n = 43) | - | No effect |
| Lung cancer patients (n = 84) | 39–59 (n = 31) vs. 60–69 (n = 34) vs. ≥70 (n = 19) | ||
| Sozzi et al., 2003 | Lung cancer patients(n = 100)Mean age: 65.1 ± 8.9 | ≤60 vs. 61–71 vs. ≥72 | Significantly higher with increasing age |
| Tamkovich et al., 2005 | Healthy participants (n = 35 [15 M + 20 W]) | 18–53 | No effect |
| Zhong et al., 2007 | Healthy adults | 20–40 vs. 41–60 vs. >60 | No effect (men and women mixed)Significantly higher cirDNA for >60 years old compared to 20–40 and 41–60 groups in women only |
| Lee et al., 2011 | Lung cancer patients (n = 134) | ≤65 (n = 108) vs. >65 (n = 26) | No effect (p=0.333) |
| Beiter et al., 2011 | Recreational runners (n = 53)Mean age: 34.8 | 17–60 years | No effect |
| Jylhävä et al., 2011 | Control (n = 11, females, 22–37 years old) vs. nonagenarians (n = 12, females, born 1917) | Significantly higher in elderly (p=0.035, < 0.001, 0.015)* | |
| Jylhävä et al., 2013 | Young controls (n = 30 [9 M + 21 W], aged 19–30 years old) vs. nonagenarians (n = 144 [43 M + 101 W], aged ≥90 years old) | Significantly higher in nonagenarian group (p=0.002) | |
| Kim et al., 2014 | Control (n = 34)Mean age = 63.79 ± 6.76 years | <65 vs. ≥65 | No effect |
| Gastric cancer patientsMean age = 66.72 ± 13.16 years | Significantly higher with increasing age | ||
| Spindler et al., 2014 | Metastatic colorectal cancer patients (n = 86)Median age: 66 (37–83) | <66 (n = 43) vs. >66 (n = 43) | No effect |
| Jylhävä et al., 2014 | Women (n = 366–409, mean age 60.48 [8.98]) | Significantly higher with increasing age (p=0.002) | |
| Women (oestrogen HRT user, n = 131–148, mean age 58.57 [6.88]) | No effect (p=0.391) | ||
| Women (oestrogen + progestin HRT user, n = 87–98, mean age 57.23 [6.39]) | No effect (p=0.869) | ||
| Men (n = 609–681), mean age (58.31 [7.91]) | No effect (p=0712) | ||
| Breitbach et al., 2014a | Male athletes (n = 26 [13 handball players + 13 triathletes])Mean age 24.7 (3.1) | No effect | |
| Jeong et al., 2015 | Haemodialysis patients (n = 95) | 58 ± 1.5 | No effect |
| Haemodialysis patients (n = 95) | 58 ± 1.5 | No effect (p=0.80) | |
| Diabetic haemodialysis patients (n = 50) | 66.4 ± 1.8 | No effect (p=0.93) | |
| Spindler et al., 2015 | Metastatic colorectal cancer patients (n = 223)Median age: 63 (35-82) years old | ≤63 (n = 119) vs. >63 (n = 104) | No effect (p=0.39) |
| Korzeneva et al., 2015 | Average age for all groups: 48.5 ± 16.3 years | ||
| Never-exposed control group (n = 109) | *21–86 | No effect (p=0.13) | |
| Chronic gamma-neutron radiation-exposed group (n = 88) | *26–79 | No effect (p=0.6) | |
| Chronic tritium β-radiation-exposed group (n = 88) | *20–80 | No effect (p=0.06) | |
| Never-exposed control group (n = 109) | <65 years old vs. ≥65 years old | Significantly higher with increasing age | |
| Chronic gamma-neutron radiation-exposed group (n = 88) | <65 years old vs. ≥65 years old | Significantly lower with increasing age | |
| Chronic tritium β-radiation-exposed group (n = 88) | <65 years old vs. ≥65 years old | No effect | |
| Hsieh et al., 2016 | Oesophageal squamous cell carcinoma patients (n = 81 [70 M + 11 F]) | <60 (N = 43) vs. >60 (N = 38) | No effect (p=0.588) |
| Tosevska et al., 2016 | Institutionalised elderly aged 65–98 (n = 105) | 65–98 | No effect |
| Karlas et al., 2017 | Non-alcoholic fatty liver disease patients (n = 58) | Age (mean age 62.1 ± 11 years old) | No effect |
| Li et al., 2017 | All lymphoma patients (n = 174) | ≤60 (N = 117) vs. ≥60 (N = 57) | No effect (p=0.414) |
| Diffuse large B cell lymphoma (n = 98) | ≤60 (N = 61) vs. ≥60 (N = 37) | No effect (p=0.668) | |
| Beranek et al., 2017 | Exacerbated psoriasis vulgaris patients (n = 28 [15 M + 13 W]) | 18–69 (median age 50) | No effect |
| Teo et al., 2019 | Young (n = 3) vs. elderly (n = 3) vs. healthy centenarians (n = 3) vs. unhealthy centenarians (n = 3) | No effect | |
| Meddeb et al., 2019 | Healthy individuals (n = 104)Age range: 18–69 | <47 (n = 52) vs. ≥47 (n = 52) | Significantly higher with increasing age (p=0.009) |
| Healthy individuals (n = 104) | Young (n = 79) vs. older (n = 25)† | Significantly higher with increasing age (p=0.0026) | |
| Colorectal cancer patients (n = 118)Age range: 22–91 | <65 (n = 52) vs. ≥65 (n = 66) | No effect | |
| Colorectal cancer patients (n = 118) | Young (n = 25) vs. older (n = 93)† | No effect (p=0.913) | |
| van der Drift et al., 2010 | Healthy controls | <60 vs. ≥60 | No effect (p=0.43) |
| Lung cancer | <60 vs. ≥60 | No effect (p=0.25) | |
| Catarino et al., 2012 | Healthy controls (n = 205) | <64 vs. ≥64 | No effect (p=0.342) |
| Lung cancer patients (n = 104) | <64 vs. ≥64 | No effect (p=0.614) | |
| Wu et al., 2019 | Newly diagnosed lymphoma patients (n = 60) | <60 vs. ≥60 | No effect (p=0.4041) |
| Treated lymphoma patients (n = 107) | <60 vs. ≥60 | No effect (p=0.3127) | |
| Alghofaili et al., 2019 | Healthy volunteers (n = 275) | Correlation plot (0–57 years old; median 27 years old) | No effect (r = –0.09) |
| Caglar et al., 2020 | Thyroiditis (n = 33) | 37.6 ± 10.9 | No effect |
| Benign (n = 37) | 54.1 ± 13.1 | No effect | |
| Malignant (n = 30) | 47.8 ± 11.9 | No effect | |
| All thyroid patients (n = 100) | Significant positive correlation (p<0.05) | ||
| Bryk et al., 2019 | T2D patients | No effect (p=0.63) | |
| Bu et al., 2020 | Gastric cancer patients (n = 61) | 40–83 | No effect (p=0.323 and p=0.280)‡ |
*
Three different extraction kits.
†
Using same cutoff for both healthy and cancer cohort as the median age (56) of all individuals tested.
‡
Two different extraction kits.
HRT: hormone replacement therapy; T2D: type II diabetes.